A chronic metabolic disease in which fat buildup leads to worsening liver function that can ultimately require an organ transplant now has its first FDA-approved therapy, a once-daily pill developed ...
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM), a biotechnology company focused on discovering and developing transformative therapeutics for ...
Resmetirom significantly reduced liver stiffness in patients with compensated MASH cirrhosis, with a 6.7 kPa decrease over 2 years. The reduction in liver stiffness may lower the risk of liver-related ...
Metabolic dysfunction-associated steatohepatitis (MASH), previously called nonalcoholic steatohepatitis (NASH), is a more severe form of fatty liver disease that causes inflammation and damage. MASH ...
CONSHOHOCKEN, Pa., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis ...
CONSHOHOCKEN, Pa., July 17, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic ...
Shares of Akero Therapeutics AKRO plummeted 62.6% on Oct 10 after it announced data from the ongoing phase IIb SYMMETRY study on its lead candidate efruxifermin (“EFX”) in patients with compensated ...
Please provide your email address to receive an email when new articles are posted on . A $37 million study led by Newcastle University, University of Edinburgh and Boehringer Ingelheim is underway to ...
CONSHOHOCKEN, Pa., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis ...
Prof Quentin Anstee in his lab at Newcastle University, UK. He is leading a £30M clinical study into liver cirrhosis – the largest ever which will provide a deep dive into the functioning of a patient ...
Once primarily linked to heavy alcohol consumption, liver cirrhosis is now increasingly affecting people who have never had a drink. Experts are warning of a silent but growing health crisis driven by ...
It usually takes years for fatty liver disease to progress to cirrhosis, but several factors affect the timeline. Fatty liver disease is the buildup of fat in your liver, which can lead to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results